Supporting evidence
Pioglitazone × HbA1c
- Authoritative support
- 6
- Available studies
- 6
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Adding medications improves blood sugar control in diabetes patients.
Rct
- Comparison
- Participants received empagliflozin as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors. · Participants received pioglitazone as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors. · Participants received glimepiride as a third line therapy in addition to ongoing metformin and dpp 4 inhibitors.
- Duration / follow-up
- 3900 weeks
Relevant effects
Mean difference
0.78
Mean difference
0.89
Mean difference
0.93
Study 2 · Limited
Combination therapy improves hepatic steatosis in T2DM patients
Rct
- Comparison
- Patients received tofogliflozin as monotherapy for the first 24 weeks. · Patients received pioglitazone as monotherapy for the first 24 weeks. · Patients who completed 24 weeks of monotherapy and met the inclusion criteria were studied for an additional 24 weeks to determine the effects of the combination therapy.
- Duration / follow-up
- 24 weeks
Relevant effects
Percent change
0.73 · 0.001
Percent change
0.73 · 0.001
Percent change
0.8 · 0.0001
Study 3 · Included
Combination therapy improves liver health in type 2 diabetes
Rct
- Comparison
- Participants received a combination of PIO and EMPA daily for 24 weeks. · Participants received PIO alone daily for 24 weeks. · Participants received EMPA alone daily for 24 weeks.
- Duration / follow-up
- 24 weeks
Relevant effects
Absolute change
1.3 · 0.003
Absolute change
1.3 · 0.003
Absolute change
1.3 · 0.003
Study 4 · Included
Lobeglitazone improves glycaemic control in type 2 diabetes patients
Rct
- Comparison
- Patients received lobeglitazone as an add on treatment for type 2 diabetes. · Patients received a placebo as a comparator to lobeglitazone.
- Duration / follow-up
- 52 weeks
Relevant effects
Mean difference
0.71 · 0.001
Percent change
35.3 · 0.001
Mean difference
0
Percent change
0
Study 5 · Included
Pioglitazone improves glycemic control compared to dapagliflozin in type 2 diabetes
Rct
- Comparison
- Patients received pioglitazone (25 mg/15 mg) once daily, along with metformin twice daily. · Patients received dapagliflozin (10 mg) once daily, an alogliptin tablet (25 mg) once daily, and metformin tablets twice daily.
- Duration / follow-up
- 4 weeks
Relevant effects
Mean difference
0.75
Mean difference
0.88
Study 6 · Limited
Saroglitazar improves liver health and glycemic control in type 2 diabetes
Rct
- Comparison
- Participants received pioglitazone 15 mg once daily for 12 months. · Participants received saroglitazar 4 mg once daily for 12 months.
- Duration / follow-up
- 52 weeks
Relevant effects
Absolute change
0.81 · 0.0001
Absolute change
0.81 · 0.0001